1	Subtracting the background: Reducing cell-free DNA's confounding effects on
2	Mycobacterium tuberculosis quantitation and the sputum microbiome
3	
4	Authors: Charissa C. Naidoo ^{a,b†} , Rouxjeane Venter ^{a†} , Francesc Codony ^c , Gemma Agustí ^d ,
5	Natasha Kitchin ^e , Selisha Naidoo ^f , Hilary Monaco ^g , Hridesh Mishra ^{a,h} , Yonghua Li ⁱ , Jose C.
6	Clemente ^g , Robin M. Warren ^a , Leopoldo N. Segal ⁱ , Grant Theron ^{a,b #}
7	
8	[†] Contributed equally
9	[#] Address correspondence to Grant Theron, <u>gtheron@sun.ac.za</u> .
10	
11	Affiliations:
12	^a DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African
13	Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology
14	and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University,
15	Cape Town, South Africa.
16	^b African Microbiome Institute, Faculty of Medicine and Health Sciences, Stellenbosch
17	University, Cape Town, South Africa.
18	^c Municipal Laboratory – Aigües de Mataró, Mataró, Spain.
19	^d Reactivos para Diagnóstico, Setmenat, Spain.
20	^e Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch
21	University, Cape Town, South Africa.
22	^f Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences,
23	University of Cape Town, Cape Town, South Africa.
24	^g Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai,
25	New York, NY, USA.

26	^h Public Health Research Institute, New Jersey Medical School, Rutgers, The State						
27	University of New Jersey, Newark, NJ, USA.						
28	ⁱ Division of Pulmonary, Critical Care, and Sleep Medicine, New York University School of						
29	Medicine, New York, USA.						
30							
31	Running title: Removing cell-free DNA for Mtb quantitation						
32							
33	Abstract word count: 250 words						
34	Text word count: 3407 words						
35							
36	Keywords: PEMAX, propidium monoazide, DNasel, Mycobacterium tuberculosis, Xpert						
37	MTB/RIF, sputum microbiome						
38							
39							
40							
41							
42							
43							
44							
45							
46							
47							
48							
49							
50							
51							

52 Abstract

Characterising DNA in specimens from people with tuberculosis (TB), a major cause of 53 54 death, is critical for evaluating diagnostics and the microbiome, yet extracellular DNA, more 55 frequent in people on chemotherapy, confounds results. We evaluated whether nucleic acid 56 dyes [propidium monoazide (PMA), PEMAX] and DNasel could reduce this. PCR [16S 57 Mycobacterium tuberculosis complex (Mtb) qPCR, Xpert MTB/RIF] was done on dilution 58 series of untreated and treated (PMA, PEMAX, DNasel) Mtb. Separately, 16S rRNA gene 59 qPCR and sequencing were done on untreated and treated patients' sputa before (Cohort A: 60 11 TB-negatives, 9 TB-positives; Cohort B: 19 TB-positives, PEMAX only) and after 24 61 weeks of chemotherapy (only Cohort B). PMA and PEMAX reduced PCR-detected Mtb DNA 62 for both the dilution series and Cohort A sputum versus untreated controls, suggesting non-63 intact Mtb is present before treatment start. PEMAX enabled sequencing Mycobacteriumdetection in 5/9 (59%; Cohort A) and 2/3 (67%; Cohort B week 0) TB-positive sputa where 64 65 no reads otherwise occurred. In Cohort A, PMA- and PEMAX-treated versus untreated sputa 66 had decreased α- and increased β-diversities. In Cohort B, α-diversity differences between 67 untreated and PEMAX-treated sputa occurred only at 24-weeks and β -diversity differences 68 between timepoints were only detected after PEMAX. DNasel had negligible effects. PMA 69 and PEMAX (but not DNasel) reduced extracellular DNA, improving the proportion of 70 Mycobacterium reads and PCR detection. PEMAX detected chemotherapy-associated 71 changes in the microbiome otherwise missed. Our findings suggest these dyes improve 72 characterization of the microbiome, especially chemotherapy-associated changes, and 73 should be included in respiratory microbiome research in TB.

74 Introduction

Tuberculosis (TB) kills an estimated 1.2 million people annually.¹ Although sensitive tests like Xpert MTB/RIF (Xpert) are available for *Mycobacterium tuberculosis* complex (*Mtb*) detection, PCR can be confounded by DNA from non-intact cells, including from previous TB.²⁻⁴ This problem can be significant: in some settings up to 35% of notifications have recurrent TB; requiring special consideration in diagnostic algorithms³. The ability to distinguish *Mtb* DNA from old versus new episodes is therefore of clinical and epidemiological significance.

82

83 The microbiome can, in addition to the pathogen itself, influence the host immune system⁷. 84 Characterising the role of microbial populations could unveil new targets for controlling TB. 85 Unlike most other infectious diseases with short chemotherapy durations, TB requires ≥ 6 86 months of antibiotics with broad-spectrum rifamycins and potentially fluoroquinolones. These antibiotics have bactericidal effects,^{10,11} resulting in extracellular DNA accumulation that, in 87 88 the case of Mtb DNA, can persist for years especially in people with compromised immunological clearance such as people living with HIV.¹² Characterisations of the 89 90 microbiome in people receiving (or who have received) TB chemotherapy thus likely 91 measure total bacterial DNA, rather than only the subset within intact (and hence live) cells.

92

Viability dyes such as ethidium monoazide (EMA), propidium monoazide (PMA), and PEMAX (a EMA and PMA formulation) have been widely used for discriminating intact from non-intact microbial cells¹³⁻¹⁷ and act by passing through compromised membranes of nonintact cells (e.g., following heat exposure or repeated freeze-thaw²⁰), after which they covalently cross-link with DNA to irreversibly form complexes not amplifiable by PCR²¹. As a result, only DNA from intact cells is, in theory, amplified once unbound dye is removed. PMA is more effective than EMA in excluding DNA from non-intact cells due to higher charge²².

PEMAX was developed to overcome limitations of PMA and EMA such as the inability to
 bind DNA from cells that are still intact but no longer metabolically active and thus may
 improve specificity.²³

103

These dyes have some data when applied to Mtb^{24-28} . For example, the addition of PMA to 104 105 Xpert shows potential for treatment monitoring, however, specificity remains an issue. More 106 data are needed as dye penetration through Mtb's waxy cell wall may be suboptimal (especially in specimens with high bacillary load)²⁹ and sputum from diseased individuals 107 108 contains high levels of host and microbial extracellular DNA that sequesters dye away, 109 leaving insufficient dye to subtract background DNA. Combining viability dyes with 16S rRNA 110 gene sequencing could improve the accuracy of microbial taxonomy by reducing background 111 from non-intact taxa that, by virtue of their lack of viability, are unlikely to play a direct 112 biological role.

113

We investigated the effects of nucleic acid dyes (PMA, PEMAX) and DNasel on 1) *Mtb* PCR detection (16S, Xpert) in a dilution series (with versus without antibiotics, heat kill, freezethaw) and sputum from people with presumptive TB as well as 2) changes in the microbiome (compared by TB status and duration of chemotherapy exposure) by comparing sputum treated or untreated with dyes and DNasel. Our overarching goal was to assess whether usage of dyes and/or DNasel could enhance the detection of intact *Mtb* (*in vitro* and in sputum) and enhance analysis of the sputum microbiome.

- 121
- 122
- 123
- 124

125

126

127 Methods

- 128 Ethics
- 129 This study was approved by the Stellenbosch University Health Research Ethics Committee
- 130 (N14/10/136, N16/05/070, M15/10/041).
- 131
- 132 In vitro dilution series using Mycobacterium tuberculosis cells
- 133 Culture

Mtb H37Rv was cultured (37°C) to an OD_{600nm} of 1.0 in 20mL Middlebrook 7H9 liquid
medium with 10% oleic acid, albumin, dextrose, and catalase (OADC; BD Diagnostics,
Johannesburg, South Africa), 0.5% glycerol and 0.05% Tween-80 (Sigma-Aldrich,
Modderfontein, South Africa). One millilitre aliquots were frozen (-80°C).

138

139 Antibiotic exposure (Experiment A)

140 Two hundred microlitres of thawed stock was inoculated into each of six flasks with 20mL 141 7H9 and incubated until mid-log (OD_{600nm} 0.6-0.8). Isoniazid (0.2g/mL in nuclease-free water; 142 Thermo Fisher Scientific, Waltham, USA) and rifampicin (1g/mL in dimethyl sulfoxide; 143 Sigma-Aldrich, Modderfontein, South Africa) were added to three of the 20mL culture flasks 144 (three additional flasks served as non-antibiotic controls) (Figure 1A). All six flasks were 145 incubated for 24-, 48-, and 72h at 37°C. To generate a 1:1 mixture of intact and non-intact 146 cells, 5mL of the non-antibiotic and antibiotic-containing cultures after different incubation 147 periods (24-, 48-, 72h) were combined in a separate sterile flask and, from each, a 100-fold serial dilution was done (10⁸, 10⁶, 10⁴ CFU/ml) in 7H9 to a total volume of 10 ml. This was 148 149 done for three biological replicates.

150

151 Heat kill (Experiment B)

152	For heat-kill experiments, a single culture was grown to mid-log, 100-fold dilutions (10 ⁸ , 10 ⁶
153	CFU/ml) done and 500 μ L of each dilution done as stated above, heated (100°C, 30 min) and
154	cooled to room temperature (RT). This was done for three biological replicates.
155	
156	Freeze-thaw (Experiment C)
157	A freeze-thaw (FT) experiment was done with 10 ⁶ dilutions after 24-, 48- and 72h incubation
158	periods that were frozen (-20°C) and allowed to thaw at RT. One biological replicate was

160

159

161 Treatment of samples to remove background DNA

162 PMA and PEMAX treatment (Experiments A-C)

done due to consumable unavailability.

163 For Experiments A and B, 500µL of each dilution was aliquoted into 1) an empty DNA 164 LoBind tube (Eppendorf, Hamburg, Germany) without further treatment (hereafter referred to 165 as untreated), 2) a LoBind tube containing 50µM PMA (Biotium, Fremont, USA) and 3) a 166 PEMAX monodose tube (GenIUL, Barcelona, Spain). PMA- and PEMAX-containing tubes 167 were vortexed for 5s before incubation in the dark (30min, 37°C). To crosslink dyes with DNA, photoactivation using the Phast Blue system (GenIUL; 60W, 2min for PMA, 15min for 168 169 PEMAX) was done. PEMAX-treated samples were transferred to new LoBind tubes (PEMAX 170 monodose tubes are hydrophilic and may cause DNA to not be neutralised by the dye¹³). 171 The same was done for Experiment C except only PEMAX was used. At the end of dye 172 treatment, samples were frozen (-20°C) for batched DNA isolation.

173

174 DNasel treatment (Experiments A and B)

This was done for the 48h timepoint only. 500µL of each dilution was aliquoted into an empty
LoBind tube (hereafter referred to as untreated) or a LoBind tube containing 1µL of RQ1
RNase-Free DNase 10X Reaction Buffer (400mM Tris-HCl, 100mM MgSO₄, 10mM CaCl₂;

Promega, Madison, USA) and 1 μ L RQ1 RNase-Free DNasel (1U/ μ g DNA; Promega) and incubated (37°C, 30min) (hereafter referred to as treated). The treated tube was further incubated (65°C, 10min) with 1 μ L of RQ1 DNase Stop Solution and cooled to RT. Samples were frozen (-20°C) for batched DNA isolation.

182

183 Sputum processing

184 Cohort A

185 Sputa from 20 people with presumptive TB were decontaminated with a modified 186 decontamination protocol{Nikolayevskyy, 2015 #161} omitting sodium-hydroxide (to preserve 187 bacterial viability) and an equal volume of N-acetyl-L-cysteine (NALC; Sigma-Aldrich) 188 solution (0.5% w/v NALC, 2.7% w/v trisodium citrate) for 15min at RT, followed by 189 neutralisation with a double phosphate buffer volume (BD Diagnostics) and centrifugated 190 (3000xg, 15min). Pellets were resuspended in 5mL phosphate buffer and biobanked (-20°C) 191 for PMA, PEMAX or DNasel treatment as described earlier (Figure 1B). People classified as 192 TB-negative (n=11) if they were MTBC culture-negative (or, if their culture was 193 contaminated, sputum Xpert negative; n=1) or TB-positive (n=9) if they were MTBC culture-194 positive (or, if culture-contaminated, sputum Xpert-positive; n=2).

195

196 Cohort B

Sputum from 23 people with multidrug resistant (MDR)-TB at two timepoints (before or shortly after chemotherapy start, after 24 weeks chemotherapy) were decontaminated and pellets resuspended in 2mL phosphate buffer, from which one 500µL aliquot was immediately PEMAX-treated as described above and the other left as is. Both aliquots were stored at -20°C for batched DNA isolation (**Figure 1C**).

202

203 Microbial DNA isolation

204 DNA was isolated from the Experiments A-C dilution series using the QIAgen DNA Mini Kit 205 (QIAGEN, Hilden, Germany) with modifications. Briefly, aliquots were heat-killed (95°C, 206 15min), resuspended in lysozyme-containing (10mg/ml) lysis buffer, incubated (1h, 37°C), 207 and proteinase K digestion done (56°C, 30min) before isolation. DNA was isolated from 208 Cohort A and B sputum using the Purelink Microbiome DNA Purification Kit (Invitrogen, 209 Carlsbad, USA) per manufacturer's instructions³⁰.

210

211 <u>16S rRNA gene characterisation</u>

212 Quantitative real-time PCR (qPCR) (Experiments A-C)

213 Reactions comprised of 5µL iTag Universal SYBR Green (Thermo Fisher Scientific, 214 Massachusetts, United States), 0.3µL of each forward and reverse primer (10µM), 1.4µL 215 nuclease-free water and 3µL template DNA were done using the CFX Connect Real-Time 216 PCR Detection System (Bio-Rad, Fremont, USA). Mtb-specific primers were used for the dilution series and universal 16S rRNA primers³¹ used for sputum (Cohorts A and B) 217 218 (Supplementary Table 1). Cycling conditions were 95°C for 5min followed by 35 cycles of 219 95°C for 5s and 60°C for 30s. All reactions were in three technical replicates and cycle 220 thresholds (C_T ; number of cycles before product detected) recorded. In each experiment, 221 non-template control (NTC) C_Ts were averaged to derive a positivity threshold.

222

223 Detection of viable bacilli by Xpert MTB/RIF (Experiments A and B)

500µL of each dilution (10^4 , 10^6 , 10^8 CFU/ml) were Xpert-tested (**Figure 1**). Aliquots were either first treated with PMA, PEMAX or DNasel as described above or were untreated. The manufacturer-recommended input volume of the (un)treated dilution (500µl) was used for PEMAX Xpert testing³². Therefore, Xpert Sample Reagent (1.5mL) was added to each 500µl aliquot and incubated (RT, 15min) with intermittent shaking before 2mL of the mixture tested (version G4; Cepheid, USA). Xpert only reports C_{Tmin} for positive results.

230

231 Sequencing and analysis

Sequences (V4 region, 150bp paired-end) generated by Illumina MiSeq as described ^{33,34} 232 were demultiplexed (QIIME 2; v2020.2)³⁵ and denoised (DADA2)³⁶. Taxonomic classification 233 was done with the Naïve Bayes classifier trained on Greengenes 13.8 reference database³⁷ 234 (pre-clustered at 99% identity with 515F/806R primers selected³⁸). BIOM tables were 235 236 rarefied by random subsampling to equal depth. Potential contaminants (in blank dyes, DNasel and reagents) were identified using *decontam* (v1.22.0)³⁹ with a threshold of 0.5 237 238 based on their prevalence in sputum vs. background samples. Contaminant amplicon 239 sequencing variants (ASVs) were not removed but highlighted if later identified as discriminatory. α - and β -diversities were calculated using vegan (v2.6-4)⁴⁰. Data and code 240 241 will be available upon publication.

242

243 <u>Statistical analysis</u>

244 The Kruskal-Wallis test with Dunn's multiple comparisons was used to compared untreated 245 and dye-treated C_T values (Experiments A-C). The Wilcoxon matched-pairs signed rank test 246 was used for sputum qPCR (Cohort A) and Xpert results. One-sided tests were used 247 because we hypothesised that dyes would improve Mtb detection. P-values are for 248 comparisons between untreated and treated (PMA, PEMAX, or DNasel) and were not 249 calculated for C_T exceeding that of the non-template control. The Friedman test with Dunn's 250 multiple comparisons was used to compare α-diversity between untreated and treated sputa 251 (Cohorts A and B). Bray-Curtis distances were compared using Kruskal-Wallis with Dunn's multiple comparisons. *DESeq2* (v1.42.0)⁴¹ (with Benjamini–Hochberg multiple comparisons) 252 253 was used for differential abundance testing. Feature tables were pruned to >1% relative 254 abundance in >1% of samples. Analyses were done using GraphPad Prism (v8.0.1) and R 255 (v4.3.2). p≤0.05 and Q-values <0.2 were significant.

256 Results

257 <u>PMA and PEMAX treatment reduce *Mtb* DNA detection in dilution series (Experiments A and </u>

258 <u>B)</u>

- 259 16S rRNA qPCR readouts
- Dye-treated aliquots had lower detected mycobacterial load (increased C_T) than untreated controls (**Figure 2A-B**). The same finding occurred using combinations of antibiotic-exposed or heat-killed cells, as well as different incubation periods (48h, 72h; **Supplementary Figure**
- **1).** FT resulted in lower detected mycobacterial load [24h non-antibiotic: ΔC_T 2.13 (95% CI:
- 1.25–2.99)] compared to pre-FT samples, but when the same FT vs. pre-FT comparison was
- 265 done for PEMAX-treated aliquots, a larger decrease in detected load occurred [24h non-
- antibiotic: $\Delta C_T 6.44 (5.53-7.36)$] (Supplementary Figure 2).

267

268 Xpert

Dye reduced load readouts vs. untreated controls regardless of if aliquots underwent antibiotic or heat or no exposure (**Figure 2C-D**).

271

272 <u>DNasel treatment does not reduce *Mtb* DNA detection in dilution series (Experiment A and
 273 <u>B</u>)
</u>

DNasel had no effect on C_T compared to untreated controls. Only the antibiotic-exposed cells showed, after DNasel treatment, unexpectedly higher detected mycobacterial load [for example, the 10⁸ CFU/ml dilution had median (IQR) C_T s of 19.24 (19.02-19.42) vs. 19.32 (19.24-20.96) for untreated; p=0.014] (**Supplementary Figure 3**). There was no significant difference in DNasel-exposed aliquots tested with Xpert (**Supplementary Figure 4**).

279

280 Sputa from presumptive tuberculosis patients are abundant in extracellular bacterial DNA

281 (Cohort A)

282

283 PMA, PEMAX, and DNasel's effect on PCR quantitation and sputum α - and β -diversity

qPCR: Decontaminated sputum treated with PMA or PEMAX had lower measured
 load than untreated controls (Figure 3A) whereas no differences in load resulted from
 DNasel-treatment.

287 Sequencing: PMA- and PEMAX-treated sputum had lower q-diversity, whereas 288 DNasel-treated sputum had similar α -diversity to paired untreated controls (Figure 3B). β -289 diversity differed between untreated and PMA-treated (p=0.006), untreated and PEMAX-290 treated (p=0.041), and PMA-treated and DNasel-treated sputum (p=0.019) (Figure 3C). 291 Paired β-diversity distances between PMA- or PEMAX-treated and untreated sputum were 292 greater than those between DNasel-treated and untreated sputum (Figure 3D). Results 293 remained similar when TB-positive and TB-negative groups were separately analysed 294 (Supplementary Figure 5A-B).

295

PMA treatment reveals more taxa (versus untreated controls) than PEMAX, however, only
 PEMAX permits Mycobacterium detection

298 PMA permitted 19 more differentially abundant taxa to be identified vs its untreated controls 299 (seven enriched, 12 depleted; Scardovia most enriched, Corynebacterium most depleted) 300 (Figure 3E), than PEMAX [one enriched (Mycobacterium), one depleted (Neisseria), one 301 identified as a potential contaminant (Bosea)] (Figure 3F; Supplementary Figures 6-7). 302 None of the seven taxa enriched due to PMA were Mycobacterium. In PEMAX-treated 303 sputum from people with TB, 6/9 (67%) had an increase in detected Mycobacterium relative 304 abundance compared to untreated sputa (p=0.031) (Figure 3G) [5/9 (56%) of these would 305 have not had any mycobacterial reads detected if PEMAX was not used]. No discriminatory 306 taxa were associated with DNasel treatment. After stratification by TB status, similar results 307 with fewer differential taxa occurred (Supplementary Figure 8).

308

309	PMA	and	PEMAX	improve	characterisation	of	microbiome	differences	by	ΤB	status
310	сотр	ared t	to untreat	ed control	's						

311 In untreated sputum, no α - and β -diversity differences occurred by TB status with 312 Gallibacterium being the most discriminatory (enriched in TB-negatives). Upon PMA or 313 PEMAX treatment, similar results occurred with Scardovia additionally enriched in TB-314 negatives (Figure 4A-E, Supplementary Figure 9). Mycobacterium was additionally 315 enriched in TB-positives after PEMAX. A comparison of Mycobacterium relative abundances 316 stratified by TB status and treatment method showed Mycobacterium enriched in PMA- and 317 PEMAX-treated sputa from TB-positives (p=0.026 and p=0.002, respectively) (Figure 4F). 318 No discriminatory taxa were found between patient groups with DNasel treatment.

319

320 PEMAX treatment reveals diversity changes from TB chemotherapy otherwise undetected 321 (Cohort B)

322 Comparisons within timepoints (untreated versus treated)

323 α -Diversity differed only at week 24, not week 0, between treated and untreated sputa, with 324 lower α -diversity observed after PEMAX (Figure 5A; p=0.033). There were no β -diversity 325 differences at week 0 nor week 24 (Figure 5B). No taxonomic differences were found at

326 week 0 in treated versus untreated sputum, however, at week 24, treated sputa were 327

328

329 Comparisons within treatment groups (week 0 versus week 24)

Neisseria-enriched and *Mogibacterium*-depleted (Figure 5C).

330 α -Diversity was unchanged per patient between timepoints (Figure 5A). β -diversity only 331 changed over time in treated sputa (Figure 5B; p=0.007). In untreated sputa, 332 Bifidobacterium and other taxa were enriched at week 0 vs. week 24 (Figure 5D). However, 333 in treated sputum, these taxa were absent and other differences occurred (Figure 5E).

334 Discussion

335 We demonstrated 1) PMA- and PEMAX-treated samples and sputum have lower detected 336 mycobacterial load compared to untreated counterparts, 2) PMA- and PEMAX treatment of 337 sputa reduces α -diversity and results in β -diversity differences compared to paired untreated 338 sputum, 3) Mycobacterium is enriched in PEMAX-treated sputum from TB-positives 339 compared to TB-negatives, a difference that was not seen in untreated sputum, 4) 340 chemotherapy-associated microbiome changes are clearer (i.e., communities are 341 compositionally dissimilar) in sputum treated with PEMAX versus those not treated, and 5) 342 DNasel treatment produces inconsistent signals in *in vitro* experiments and does not 343 influence microbiome estimates. Together, these data have implications for characterising 344 pathogen load and the microbiome in people with TB, including evaluating the effect of TB 345 chemotherapy.

346

347 PMA and PEMAX improve differentiation of live from dead foodborne pathogens such as Salmonella, Campylobacter, and Listeria⁴². PMA also preferentially excludes dead rather 348 than live *Mtb* in smear-positive sputa^{27,29,43}, however, no studies have evaluated PEMAX in 349 350 TB. Lower detected mycobacterial load was found with PMA and PEMAX treatment in PCR 351 (qPCR, Xpert) implying some bacilli even from laboratory-generated dilution series are not 352 intact. The effects of PMA, PEMAX, and DNasel were not as strong as expected in the 353 presence of increased cellular membrane disruption caused by antibiotics and heat killing 354 (for example, PCR results becoming negative). This corroborates earlier Xpert data showing imperfect specificity and minimal improvement with PMA pre-treatment.²⁴ 355

356

357 Compared to paired untreated samples, PMA- and PEMAX-treated samples had lower 358 microbial richness (i.e., suppressed DNA signals from non-intact bacteria). The inclusion of 359 PMA or PEMAX is thus important for removing taxa likely not biologically active. These

360 methods further identified *Mycobacterium* in people with TB that would otherwise go 361 undetected. Previously, we demonstrated how a nested mycobacteriome approach could 362 help to resolve this⁸; dye treatment represents an alternative. This is relevant for microbiome 363 studies involving people with TB, as we and others have shown that *Mycobacterium* reads 364 are often undetectable by 16S rRNA gene sequencing in sputum.^{44,45}

365

Prolonged exposure to TB chemotherapy, particularly those with broader antimicrobial spectra that are common in treatment regimens for drug-resistant TB, and host immunological responses are likely to produce non-viable bacterial populations¹². PEMAX improved detection of microbiome changes in sputum before and after chemotherapy by detecting more discriminatory taxa. It is worth considering if previously documented treatment-related sputum microbiome changes^{46,47} overlooked any taxonomic changes that could have been detected using a viability dye.

373

DNasel performed poorly in dilution series and sputum microbiome evaluations. Prior research had suggested that the presence of antibiotics increased DNasel sensitivity⁴⁸, but this was not the case, which may be related to differences in specimen type or bacterial species.

378

The results must be viewed in the context of its limitations. Xpert assays was done using a dilution series of cells instead of sputum, in which cells are embedded within a matrix, which may affect results. Furthermore, sputum decontamination processes (commonly done as part of TB microbiology) can cause cell death while leaving cell membranes intact, in which case PMA and EMA have lower reduced ability to remove background DNA. This, however, is one reason we used PEMAX, which was designed to overcome this constraint¹⁶. Moreover, we used a modified sputum decontamination procedure⁴⁴ in which sodium

hydroxide was omitted to minimise effects on bacterial viability. Some study participants
(Cohort B, who had MDR-TB) may have already been on chemotherapy at week 0, however,
it is difficult to obtain a true baseline specimen from such people who are often prescribed
first-line chemotherapeutics before drug resistance is discovered.

390

As sputum is an imperfect surrogate for the lower airways, many studies are shifting to bronchoalveolar lavage (BAL) sampling. Pre-treating low biomass specimens, such as BAL fluid or cough aerosols, where background signals from medical equipment or PCR reagents (or "reagent microbiome") can interfere with biological interpretation,⁵¹ is likely to be beneficial, but further validation is required.

396

Our findings highlight the critical role of PMA or PEMAX pre-treatment in TB respiratory microbiome research, particularly during chemotherapy, as it provides invaluable insights into bacterial load characterisation and microbiome dynamics, especially when considering chemotherapeutics.

402 Acknowledgements

403 This work was supported by the South African National Research Foundation (#98948) and 404 the South African Medical Research Council (SAMRC) through its Division of Research 405 Capacity Development under the SAMRC Intramural Postdoctoral programme from funding 406 received from the South African National Treasury. The content hereof is the sole 407 responsibility of the authors and do not necessarily represent the official views of the 408 SAMRC or the funders. CN and research reported in this publication was supported by the 409 Fogarty International Center of the National Institutes of Health under Award Number 410 K43TW012302. The content is solely the responsibility of the authors and does not 411 necessarily represent the official views of the National Institutes of Health. RV is supported 412 by an NRF PDP Postdoctoral fellowship through the SAMRC, the DSI-NRF Centre of 413 Excellence for Biomedical Tuberculosis Research and the Faculty of Medicine and Health 414 Sciences at Stellenbosch University. GT acknowledges funding from National Institute of 415 Allergy and Infectious Diseases of the National Institutes of Health under award number 416 R01AI136894, EDCTP programme supported by the European Union (TMA-2015-SF-1041), 417 and the SAMRC Intramural Flagship Project. Computations were performed using facilities 418 provided by the University of Cape Town's ICTS High Performance Computing team: 419 https://hpc.uct.ac.za/.

420

421 Conflict of Interest

422 GT acknowledges in-kind donations from Cepheid. GT declares no other competing 423 interests. The other authors each declare no competing interests.

424

425 Data availability

- 426 The data that support the findings of this study will be openly available in the Sequence
- 427 Read Archive at <u>https://www.ncbi.nlm.nih.gov/sra</u>. Other supporting data generated in this
- 428 study are available from the corresponding author on reasonable request.

429 References

430 1. World Health Organization. Global Tuberculosis Report 2023.

431 2. Theron G, Venter R, Calligaro G, et al. Xpert MTB/RIF results in patients with
432 previous tuberculosis: can we distinguish true from false positive results? *Clinical Infectious*433 *Diseases* 2016; **62**(8): 995-1001.

Mishra H, Reeve BW, Palmer Z, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF for
diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous
tuberculosis: a two-cohort diagnostic accuracy study. *The Lancet Respiratory Medicine*2020; 8(4): 368-82.

438 4. Theron G, Venter R, Smith L, et al. False-positive Xpert MTB/RIF results in retested
439 patients with previous tuberculosis: frequency, profile, and prospective clinical outcomes.
440 *Journal of clinical microbiology* 2018; **56**(3).

Jacobs R, Malherbe S, Loxton AG, et al. Identification of novel host biomarkers in
plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of
tuberculosis treatment response. *Oncotarget* 2016; **7**(36): 57581.

Goletti D, Arlehamn CSL, Scriba TJ, et al. Can we predict tuberculosis cure? What
tools are available? *European Respiratory Journal* 2018; **52**(5).

7. Namasivayam S, Diarra B, Diabate S, et al. Patients infected with Mycobacterium
africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota. *PLoS neglected tropical diseases* 2020; **14**(5): e0008230.

8. Sulaiman I, Wu BG, Li Y, et al. Evaluation of the airway microbiome in
nontuberculous mycobacteria disease. *European Respiratory Journal* 2018; **52**(4).

9. Diallo D, Somboro AM, Diabate S, et al. Antituberculosis therapy and gut microbiota:
review of potential host microbiota directed-therapies. *Frontiers in Cellular and Infection Microbiology* 2021; **11**: 673100.

10. Namasivayam S, Maiga M, Yuan W, et al. Longitudinal profiling reveals a persistent
intestinal dysbiosis triggered by conventional anti-tuberculosis therapy. *Microbiome* 2017;
5(1): 1-17.

457 11. Burdet C, Nguyen TT, Duval X, et al. Impact of antibiotic gut exposure on the
458 temporal changes in microbiome diversity. *Antimicrobial agents and chemotherapy* 2019;
459 **63**(10).

Rogers G, Marsh P, Stressmann A, et al. The exclusion of dead bacterial cells is
essential for accurate molecular analysis of clinical samples. *Clinical microbiology and infection* 2010; **16**(11): 1656-8.

463 13. Agustí G, Codony F, Fittipaldi M, Adrados B, Morató J. Viability determination of
464 Helicobacter pylori using propidium monoazide quantitative PCR. *Helicobacter* 2010; **15**(5):
465 473-6.

14. Rawsthorne H, Dock C, Jaykus L. PCR-based method using propidium monoazide to
distinguish viable from nonviable Bacillus subtilis spores. *Applied and environmental microbiology* 2009; **75**(9): 2936-9.

Vesper S, McKinstry C, Hartmann C, Neace M, Yoder S, Vesper A. Quantifying
fungal viability in air and water samples using quantitative PCR after treatment with
propidium monoazide (PMA). *Journal of microbiological methods* 2008; **72**(2): 180-4.

472 16. Agustí G, Fittipaldi M, Codony F. False-positive viability PCR results: an association
473 with microtubes. *Current microbiology* 2017; **74**(3): 377-80.

474 17. Wagner AO, Malin C, Knapp BA, Illmer P. Removal of free extracellular DNA from
475 environmental samples by ethidium monoazide and propidium monoazide. *Applied and*476 *Environmental Microbiology* 2008; **74**(8): 2537-9.

477 18. Vondrakova L, Turonova H, Scholtz V, Pazlarova J, Demnerova K. Impact of various
478 killing methods on EMA/PMA-qPCR efficacy. *Food Control* 2018; **85**: 23-8.

479 19. Kragh ML, Thykier M, Hansen LT. A long-amplicon quantitative PCR assay with
480 propidium monoazide to enumerate viable Listeria monocytogenes after heat and
481 desiccation treatments. *Food microbiology* 2020; **86**: 103310.

Cuthbertson L, Rogers GB, Walker AW, et al. Implications of multiple freeze-thawing
on respiratory samples for culture-independent analyses. *Journal of Cystic Fibrosis* 2015;
14(4): 464-7.

485 21. Nocker A, Sossa-Fernandez P, Burr MD, Camper AK. Use of propidium monoazide
486 for live/dead distinction in microbial ecology. *Applied and environmental microbiology* 2007;
487 **73**(16): 5111-7.

488 22. Nocker A, Cheung C-Y, Camper AK. Comparison of propidium monoazide with
ethidium monoazide for differentiation of live vs. dead bacteria by selective removal of DNA
from dead cells. *Journal of microbiological methods* 2006; **67**(2): 310-20.

491 23. Hortelano I, Moreno MY, Garcia-Hernandez J, Ferrús MA. Optimization of pre492 treatments with Propidium Monoazide and PEMAX[™] before real-time quantitative PCR for
493 detection and quantification of viable Helicobacter pylori cells. *Journal of Microbiological*494 *Methods* 2021; **185**: 106223.

495 24. Kayigire XA, Friedrich SO, Karinja MN, van der Merwe L, Martinson NA, Diacon AH.
496 Propidium monoazide and Xpert MTB/RIF to quantify Mycobacterium tuberculosis cells.
497 *Tuberculosis* 2016; **101**: 79-84.

ANKOLAYEVSKYY V, Miotto P, Pimkina E, et al. Utility of propidium monoazide viability
assay as a biomarker for a tuberculosis disease. *Tuberculosis* 2015; **95**(2): 179-85.

500 26. Kim YJ, Lee SM, Park BK, et al. Evaluation of propidium monoazide real-time PCR

501 for early detection of viable Mycobacterium tuberculosis in clinical respiratory specimens.

502 Annals of laboratory medicine 2014; **34**(3): 203.

503	27. de Assunção TM, Batista Jr EL, Deves C, et al. Real time PCR quantification of
504	viable Mycobacterium tuberculosis from sputum samples treated with propidium monoazide.
505	Tuberculosis 2014: 94 (4): 421-7.

506 28. Miotto P, Bigoni S, Migliori GB, Matteelli A, Cirillo DM. Early tuberculosis treatment 507 monitoring by Xpert® MTB/RIF. *European Respiratory Journal* 2012; **39**(5): 1269-71.

508 29. Lu J, Zheng H, Chu P, et al. Direct detection from clinical sputum samples to 509 differentiate live and dead Mycobacterium Tuberculosis. *Journal of Clinical Laboratory* 510 *Analysis* 2019; **33**(3): e22716.

511 30. Invitrogen. PureLink™ Microbiome DNA Purification Kit

512 Pub. No. MAN0014267 Rev. A.0.

513 31. Caporaso JG, Lauber CL, Walters WA, et al. Global patterns of 16S rRNA diversity at

a depth of millions of sequences per sample. *Proceedings of the National Academy of Sciences* 2011; **108**(Supplement 1): 4516-22.

516 32. GenIUL. PEMAX 25 Reagent Monodose (TBC-Biomarker kit) INSTRUCTIONS Doc
517 Code 450000075-00 2015.

33. Segal LN, Clemente JC, Li Y, et al. Anaerobic Bacterial Fermentation Products
Increase Tuberculosis Risk in Antiretroviral-Drug-Treated HIV Patients. *Cell Host & Microbe*2017.

521 34. Tsay J-CJ, Wu BG, Badri MH, et al. Airway microbiota is associated with 522 upregulation of the PI3K pathway in lung cancer. *American journal of respiratory and critical* 523 *care medicine* 2018; **198**(9): 1188-98.

35. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and
extensible microbiome data science using QIIME 2. *Nature biotechnology* 2019; **37**(8): 8527.

527	36.	Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2:
528	high-re	solution sample inference from Illumina amplicon data. Nature methods 2016; 13(7):
529	581-3.	

530 37. McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with 531 explicit ranks for ecological and evolutionary analyses of bacteria and archaea. *The ISME* 532 *journal* 2012; **6**(3): 610-8.

- 38. Caporaso JG, Lauber CL, Walters WA, et al. Ultra-high-throughput microbial
 community analysis on the Illumina HiSeq and MiSeq platforms. *The ISME journal* 2012;
 6(8): 1621-4.
- 39. Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. Simple statistical
 identification and removal of contaminant sequences in marker-gene and metagenomics
 data. *Microbiome* 2018; **6**: 1-14.
- 539 40. Oksanen J, Kindt R, Legendre P, et al. The vegan package. *Community ecology* 540 *package* 2007; **10**: 631-7.
- 41. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
 RNA-seq data with DESeq2. *Genome biology* 2014; **15**(12): 550.
- Elizaquível P, Aznar R, Sánchez G. Recent developments in the use of viability dyes
 and quantitative PCR in the food microbiology field. *Journal of applied microbiology* 2014; **116**(1): 1-13.
- Kim YJ, Lee SM, Park BK, et al. Evaluation of propidium monoazide real-time PCR
 for early detection of viable Mycobacterium tuberculosis in clinical respiratory specimens. *Annals of laboratory medicine* 2014; **34**(3): 203-9.
- 44. Naidoo CC, Nyawo GR, Sulaiman I, et al. Anaerobe-enriched gut microbiota predicts
 pro-inflammatory responses in pulmonary tuberculosis. *EBioMedicine* 2021; 67: 103374.

45. Ticlla MR, Hella J, Hiza H, et al. The Sputum Microbiome in Pulmonary Tuberculosis
and Its Association With Disease Manifestations: A Cross-Sectional Study. *Front Microbiol*2021; **12**: 633396.

46. Musisi E, Wyness A, Eldirdiri S, et al. Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials. *The Lancet Microbe* 2023; **4**(11): e913-e22.

557 47. Kateete DP, Mbabazi MM, Nakazzi F, et al. Sputum microbiota profiles of treatment-558 naïve TB patients in Uganda before and during first-line therapy. *Scientific Reports* 2021;

559 **11**(1): 24486.

48. Pezzulo AA, Kelly PH, Nassar BS, et al. Abundant DNase I-sensitive bacterial DNA
in healthy porcine lungs and its implications for the lung microbiome. *Appl Environ Microbiol*2013; **79**(19): 5936-41.

49. Nocker A, Sossa KE, Camper AK. Molecular monitoring of disinfection efficacy using
propidium monoazide in combination with quantitative PCR. *Journal of microbiological methods* 2007; **70**(2): 252-60.

566 50. Codony F, Agustí G, Allué-Guardia A. Cell membrane integrity and distinguishing 567 between metabolically active and inactive cells as a means of improving viability PCR. 568 *Molecular and Cellular Probes* 2015; **29**(3): 190-2.

569 51. de Goffau MC, Lager S, Salter SJ, et al. Recognizing the reagent microbiome. *Nature* 570 *Microbiology* 2018; **3**(8): 851-3.

572

574 Figure legends

Figure 1. Experimental workflow for in vitro dilution series and sputum. *Mycobacterium tuberculosis* was cultured in flasks and a dilution series prepared for testing in three separate experiments: antibiotic exposure (Experiment A), heat-kill (Experiment B) and freeze-thaw (Experiment C). Sputum was collected from two distinct cohorts: one comprising patients with presumptive tuberculosis (Cohort A) and the other involving patients treated for drugresistant tuberculosis (Cohort B). MTBC: *Mycobacterium tuberculosis* complex.

581

582 Figure 2. PMA and PEMAX reduce MTBC detection in dilution series (regardless of 583 how aliquots were treated) and in sputum sediments from presumptive TB patients. 584 PCR readouts for non-antibiotic (cultured in absence of antibiotics), antibiotic (cultured with 585 isoniazid and rifampicin), 1:1 mixture (non-antibiotic: antibiotic), and heat-killed (non-586 antibiotic aliquots heated at 100-C for 30min) cultures after 24h of incubation. 587 **Supplementary Figure 1** has these data for the 48h and 72h exposure period. Median C_{TS} (IQR) are shown for (A) 10^8 and (B) 10^6 CFU/ml dilutions. Open circles denote C_Ts that 588 589 exceed those of the averaged non-template control (dashed line). Median Xpert C_{Tmin} (95% CI) are shown for (C) 10⁸ CFU/ml and (D) 10⁶ CFU/ml. Triangles on y-axes indicate 590 591 decreasing load. MTBC: Mycobacterium tuberculosis complex; C_{T:} cycle threshold; C_{Tmin}: 592 minimum cycle threshold;. CI: confidence interval; IQR: interguartile range.

593

Figure 3. In sputa from people with presumptive TB, PMA or PEMAX reduces microbial diversity estimates more than DNasel in comparison to untreated sputum. (A) PCR readouts for untreated versus treated (PMA, PEMAX, or DNasel) decontaminated sputum from TB-negatives and TB-positives (Cohort A). Triangles on y-axes indicate decreasing load. (B) α -Diversity decreased after PMA and PEMAX treatment but not DNasel. (C) β-diversity differences between untreated and treated groups. (D) Bray-Curtis

distance to untreated sputum was higher in PMA- and PEMAX-treated sputum versus DNasel-treated sputum. Volcano plots depicting **(E)** many differentially abundant taxa in PMA-treated versus untreated sputum and **(F)** *Mycobacterium*-enrichment and *Neisseria*depletion in PEMAX-treated versus untreated sputa. More discriminatory taxa appear closer to the left or right, and higher above the threshold (red dotted line, false discovery rate of 0.2). Relative abundances correspond to circle size. **(G)** Use of PEMAX increased the proportion of *Mycobacterium* reads in TB-positives. ASVs: amplicon sequencing variants.

607

608 Figure 4. PMA and PEMAX enhances *Mycobacterium* detection in TB-positives versus 609 **TB-negatives.** In untreated sputum, groups did not differ in (A) α -diversity nor (B) β -610 diversity. The same was observed for PMA-, PEMAX-, and DNasel-treated sputum (see 611 Supplement). TB-negatives were Gallibacterium-enriched in (C) untreated, (D) PMA-treated 612 and (E) PEMAX-treated sputum versus TB-positives. More discriminatory taxa appear closer 613 to the left or right, and higher above the threshold (red dotted line, false discovery rate of 614 0.2). Relative abundances correspond to circle size. (F) Mycobacterium relative abundance 615 was higher in TB-positives than TB-negatives in sputum treated with either PMA or PEMAX, 616 however, abundances were the same in untreated or DNase-treated sputum. In TB-617 positives, PEMAX permitted greater mycobacterial detection than PMA [0.0015 (0.0001-618 0.1125) vs. 0.0001(0.0001-0.0009)]. ASVs: amplicon sequencing variants.

619

Figure 5. Microbial changes after TB chemotherapy are only detectable with PEMAX.

(A) α-Diversity was only different between week 24 untreated and PEMAX-treated sputum.
(B) Unlike in untreated sputum, PEMAX enabled detection of β-diversity changes between
weeks 0 and 24. (C) *Neisseria*-enrichment and *Mogibacterium*-depletion at week 24 in
treated vs. untreated sputum. (D) Only three discriminatory taxa were identified in the
absence of PEMAX between weeks 0 and 24, whereas (E) many were identified after

- 626 PEMAX-exposure. More discriminatory taxa are closer to the left or right, and higher above
- the threshold (red dotted line, false discovery rate of 0.2). Relative abundances of taxa are
- 628 indicated by circle size. ASVs: amplicon sequencing variants.



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license.





(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit. It is made available under a CC-BY-NC-ND 4.0 International license.



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license.



Enriched in TB-negative Enriched in TB-positive

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license .

